Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018140733) VACCINE COMPOSITIONS OF HERPESVIRUS ENVELOPE PROTEIN COMBINATIONS TO INDUCE IMMUNE RESPONSE
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/140733 International Application No.: PCT/US2018/015459
Publication Date: 02.08.2018 International Filing Date: 26.01.2018
IPC:
A61K 39/00 (2006.01) ,A61K 39/12 (2006.01) ,A61K 39/245 (2006.01) ,A61K 39/385 (2006.01) ,A61K 39/395 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
12
Viral antigens
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
12
Viral antigens
245
Herpetoviridae, e.g. herpes simplex virus
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
385
Haptens or antigens, bound to carriers
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Applicants:
THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. [US/US]; 6720-A Rockledge Drive, Suite 100 Bethesda, MD 20817, US
Inventors:
CUI, Xinle; US
SNAPPER, Clifford, M; US
Agent:
DONALDSON, Timothy, B.; US
Priority Data:
62/451,39627.01.2017US
Title (EN) VACCINE COMPOSITIONS OF HERPESVIRUS ENVELOPE PROTEIN COMBINATIONS TO INDUCE IMMUNE RESPONSE
(FR) COMPOSITIONS DE VACCIN DE COMBINAISONS DE PROTÉINES D'ENVELOPPE D'HERPÈSVIRUS DESTINÉES À INDUIRE UNE RÉPONSE IMMUNITAIRE
Abstract:
(EN) Provided are antigenic compositions and uses thereof that include at least two human herpesvirus (HHV) polypeptides involved in mediating HHV binding, fusion, and entry into host cells, such as gp350, gH, gL, and gB, or nucleic acids encoding the polypeptides. The two HHV polypeptides comprise any combination of: a gB polypeptide; a gp350 polypeptide; a gL polypeptide; and a gH polypeptide, and optionally any one or more of the following polypeptides: gp42, gM, gN, gl, gC, gE, gD, ORF68, BMRF-2, BDLF2, UL128, UL130, UL131A, and gpK8.1. Also disclosed are methods of inducing an immune response or treating or preventing an HHV infection in a subject by administering to the subject at least two of the HHV polypeptides or nucleic acid(s) encoding the same. Methods of passively transferring immunity using high-titer anti-HHV antibodies or immune cells are also disclosed.
(FR) L'invention concerne des compositions antigéniques et des utilisations associées qui comprennent au moins deux polypeptides d'herpèsvirus humain (HHV) impliqués dans la médiation de la liaison, de la fusion et de l'entrée du HHV dans des cellules hôtes, tels que gp350, gH, gL et gB, ou des acides nucléiques codant les polypeptides. Les deux polypeptides de HHV comprennent une combinaison quelconque des suivants : un polypeptide gB; un polypeptide gp350; un polypeptide gL; et un polypeptide gH, et éventuellement un ou plusieurs des polypeptides suivants : gp42, gM, gN, gl, gC, gE, gD, ORF68, BMRF-2, BDLF2, UL128, UL130, UL131A et gpK81. L'invention concerne également des procédés d'induction d'une réponse immunitaire ou de traitement ou de prévention d'une infection par le HHV chez un sujet par l'administration au sujet d'au moins deux des polypeptides de HHV ou d'acide(s) nucléique(s) les codant. L'invention concerne également des procédés de transfert passif d'immunité au moyen d'anticorps anti-HHV à titre élevé ou de cellules immunitaires.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)